Phathom Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
Phathom Pharmaceuticals, Inc.
5.85
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Frazier Life Sciences ManagementFrazier Life Sciences | $135.3M | 17.05% | 0.00% | |
| 2 | Medicxi Ventures Management (Jersey)Medicxi Ventures Management (Jersey) | $81.0M | 10.21% | 0.00% | |
| 3 | BlackRockBlackRockindex-like | $49.1M | 6.19% | +11.40% | |
| 4 | InvescoInvesco | $43.7M | 5.51% | −6.76% | |
| 5 | Carlyle GroupCarlyle | $37.9M | 4.78% | 0.00% | |
| 6 | Millennium ManagementMillennium | $36.6M | 4.62% | −16.08% | |
| 7 | Vanguard Capital ManagementVanguardindex-like | $28.8M | 3.63% | +2.84% | |
| 8 | GW&K Investment ManagementGW&K | $23.5M | 2.96% | +52.48% | |
| 9 | Franklin ResourcesFranklin Resources | $21.4M | 2.70% | +98.17% | |
| 10 | NEA ManagementNEA | $21.3M | 2.68% | 0.00% | |
| 11 | 683 Capital Management683 Capital Management | $20.1M | 2.53% | 0.00% | |
| 12 | Goldman Sachs GroupGoldman Sachs | $19.3M | 2.43% | +183.94% | |
| 13 | State StreetState Streetindex-like | $17.2M | 2.17% | +14.38% | |
| 14 | Catalys PacificCatalys Pacific | $16.2M | 2.04% | 0.00% | |
| 15 | Delaware Management HoldingsDelaware | $15.9M | 2.00% | +21.35% | |
| 16 | Geode Capital ManagementGeodeindex-like | $14.3M | 1.80% | −0.93% | |
| 17 | Wasatch AdvisorsWasatch | $14.2M | 1.79% | −2.51% | |
| 18 | Ensign Peak AdvisorsEnsign Peak | $11.4M | 1.44% | −35.38% | |
| 19 | Propel Bio ManagementPropel Bio | $11.4M | 1.44% | +24.85% | |
| 20 | Point72 Asset ManagementPoint72 | $11.1M | 1.40% | new | |
| 21 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $8.6M | 1.09% | +19.61% | |
| 22 | SummitTX CapitalSummitTX Capital | $8.6M | 1.08% | −20.72% | |
| 23 | Hsbc HoldingsHsbc | $7.7M | 0.97% | new | |
| 24 | Citadel AdvisorsCitadel | $7.6M | 0.95% | −24.11% | |
| 25 | Marshall WaceMarshall Wace | $7.2M | 0.91% | −22.61% |
162 managers report $793.4M of Phathom Pharmaceuticals on form 13F for the quarter ended Jun 30 '26. 21 of them hold 80% of it; Frazier Life Sciences is largest at 17.05%.
Largest filed tie
—
Expected move
No implied move.
No implied move.
No implied move.